As one of the most reliable industry leaders in developing animal models of diseases, Creative Biolabs provides a large range of chemically-induced experimental diabetic mice/rats models coupled with comprehensive relevant services. Our seasoned scientists are pleased to offer custom service to meet your specific requirements.

Numerous efforts are constantly being made not only to investigate diabetes and diabetes-related complications but also to test new therapeutics for diabetes. Accordingly, a large number of animal models exist, making it necessary for investigators to carefully consider and compare before they choose the most suitable model because of their differential utility in reflecting various aspects of diabetic abnormalities. In one of these frequently used models, diabetes is induced by injection of both streptozotocin (STZ) and nicotinamide (NA) to adult rats or mice, which was first established in 1998.

STZ-NA-Induced Diabetes

In the process of induction, two chemical compounds are given: STZ and NA. STZ, a nitrosourea analogue, is a well-known diabetogenic agent that will damage pancreatic β-cells due to DNA alkylation. However, NA, the amide form of vitamin B3, partially protects these cells against the detrimental effects of STZ via attenuation of DNA damage, proinsulin biosynthesis, body weight loss, diminished pancreatic insulin content and so on.

Main Characteristics of STZ-NA-Induced Diabetes Model

Firstly, doses of STZ and NA must be adjusted to obtain the appropriate severity in this diabetic model. In comparison with diabetic models induced by STZ alone, the severity of STZ-NA-induced diabetes is relatively mild. What's more, β cells are not completely damaged and thus the insulin secretory response to glucose is only slightly diminished. Besides, they manifest moderate hyperglycemia and do not require exogenous insulin to survive. Secondly, this model remains stable for a long time, thereby making it suitable not only for short-term but also for long-term animal studies.

Streptozotocin-Nicotinamide-Induced Diabetic Model Fig.1 Changes in the levels of plasma glucose and insulin in the STZ-NA-induced diabetic rats. NC: normal control, DC: diabetic control, PS: pomegranate seed, PJ: pomegranate juice, PSJ: pomegranate seed-juice, GC: Glibenclamide. (Aboonabi et al. 2014)

Application of STZ-NA-Induced Diabetes Model

This model has proved to be useful in various diabetes-related areas. Specifically, these aspects mainly include elucidation of the potential mechanisms of diabetic complications and the evaluation of anti-diabetic properties of new agents and some natural compounds. Particularly, it is often used in studies testing blood glucose-lowering properties and insulin-secretory properties of various pharmacological and natural compounds. Moreover, this is also a suitable model to test the regenerative capacity of the endocrine pancreas.

Creative Biolabs provides various assessment options for testing the effectiveness of potential antidiabetic agents depending on your study objectives, including but not limited to:

  • Fasting Blood Glucose
  • Serum Insulin Level
  • Glucose Tolerance Test
  • Immunological Tests
  • Hyperglycemia Assessment
  • Oxidative Stress Markers
  • Histopathology

Additionally, Creative Biolabs also offers other types of rodent metabolic disease models that you may be interested in:

If you are interested in any of these services, please send us an inquiry or contact us directly for more detailed information. We are willing to share our state-of-the-art platforms and sufficient expertise with our clients to boost their brilliant studies.

Reference

  1. Aboonabi, A.; et al. Antioxidant effect of pomegranate against streptozotocin-nicotinamide generated oxidative stress induced diabetic rats[J]. Toxicology Reports. 2014, 1(2):915-922.

For Research Use Only.



Online Inquiry
Name:
*Phone:
*E-mail Address:
*Service & Products Interested:
Project Description:
Contact Us USA

Tel:
Fax:
Email:
UK

Tel:
Email:

Germany

Tel:
Email:

Follow us on:
Copyright © 2024 Creative Biolabs.